Emerging immunotherapy strategies, such as oncolytic virus therapy (OVT), adoptive cell transfer therapy (ACT), and cancer vaccines—including innovative KRAS mutant peptide-based vaccines in adjuvant settings—show promising potential across various tumor types, including PDAC [23,30]. The gene discussed is KRAS; the disease is cancer.